| Mologen AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120093804 | Concatamers for Immunemodulation - The invention relates to a polymeric, non-coding nucleic acid molecule for modulation of the activity of the human and animal immune system as well as a method for the manufacture thereof and a vaccine, comprising the polymeric, non-coding nucleic acid molecule, wherein polymeric, non-coding nucleic acid molecules may be understood as non-coding nucleic acid molecules, comprising at least four covalently bound molecules (tetramer) or are assemblies of more non-coding nucleic acid molecules (high molecular polymers) which are covalently bound to each other. | 04-19-2012 |
| 20110223189 | AGENT FOR TREATING LEISHMANIA INFECTIONS - The invention relates to using a combination of DNA-expression constructs for producing a drug for immunisation against | 09-15-2011 |
| 20100303803 | CATENATE FOR IMMUNOSTIMULATION - The invention relates to a multimeric, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a production method therefor, and to a vaccine containing said multimeric, non-coding nucleic acid molecule. Said multimeric, non-coding nucleic acid molecules can be non-coding nucleic acid molecules that consist of at least two of said molecules (dimer) or assemblies of several non-coding nucleic acid molecules. | 12-02-2010 |
| 20100297189 | ALLOGENEIC TUMOR THERAPEUTIC AGENT, A VACCINE USING ALLOGENEIC TUMOR CELLS FOR THE THERAPEUTIC TREATMENT OF TUMOR DISEASES, AND A METHOD FOR THE MAKING OF SUCH A VACCINE, AND TRANSFECTED HUMAN TUMOR CELLS FOR USE AS A VACCINE - Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner. | 11-25-2010 |
| 20090220931 | FUNCTIONAL IN VITRO IMMUNOASSAY - The invention relates to a method for the in vitro investigation of the effect of substances in in vivo processes and an in vitro detection method for the identification of immunomodulating compounds and/or the detection of the effect of immunomodulating compounds and the identification of apoptosis-inducing and/or necrosis-inducing compounds mediated by the immune system in in vivo processes. The methods according to the invention are particularly suitable for investigating effects of substances on cells, which are mediated by the immune system. Furthermore, the method according to the invention is suitable for in vitro monitoring of the in vivo effects before, during and/or after the administration of immunomodulating compounds and of apoptosis-inducing and/or necrosis-inducing compounds. | 09-03-2009 |
| 20090053250 | Immune Modulating Oligonucleotides in Connection with Chemotherapeutic Measures - The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs. | 02-26-2009 |
| 20090004703 | Method for the Production of Suitable Dna Constructs for Specific Inhibition of Gene Expression by Rna Interference - The invention relates to a method for the production of vectors which, following transfection thereof in eukaryotic cells, are suitable for targeted inhibition of the formation of defined proteins therein by RNA interference. The method for the production of such vectors does not include any PCR steps. It is a three-step procedure in a single reaction vessel and can be carried out within a few hours. Thus, a method is provided which allows very easy testing of a wide variety of siRNA sequences for their functionality within a very short time. Screening processes utilizing the rapid and uncomplicated production of vectors with the aid of said kit can be performed in a cost- and time-saving manner. Another advantage of vectors thus produced is their small size which, among other things, facilitates transfection. | 01-01-2009 |
| 20080311630 | Dna Constructs for Specific Inhibition of Gene Expression by Rna Interference - The invention relates to expression constructs for targeted inhibition of gene expression and methods for their production and which, after transfection thereof into eukaryotic cells, are suitable for inhibiting in a targeted manner these cells formation of defined proteins by RNA interference, wherein the method is a three step method requiring no PCR steps and is carried out in one reaction vessel in a few hours and are suitable for multiple gene expression inhibition. | 12-18-2008 |
